Skip Nav Destination
Issues
1 July 2010
-
Cover Image
Cover Image
High-grade gliomas are among the deadliest of human cancers and appropriate glioma mouse models that are conveniently applicable for therapy-intervention studies can contribute to the finding of more efficacious treatments. Following the intracranial injection of lentiviral Cre-recombinase vectors into LoxP-conditional p53(or pten);Ink4a/ Arf;K-Rasv12;LucR mice, noninvasively visible high-grade gliomas arise with a short tumor latency that show features commonly found in human high-grade glioma, such as a high mitotic index, nuclear atypia, pseudopalisading necrosis, and giant cell formation. For further details, please see the article by de Vries and colleagues on page 3431 of this issue. - PDF Icon PDF LinkTable of Contents
ISSN 1078-0432
EISSN 1557-3265
Highlights
Special Report
AACR-FDA-NCI Cancer Biomarkers Collaborative Consensus Report: Advancing the Use of Biomarkers in Cancer Drug Development
Samir N. Khleif; for the AACR-FDA-NCI Cancer Biomarkers Collaborative; James H. Doroshow; for the AACR-FDA-NCI Cancer Biomarkers Collaborative; William N. Hait; for the AACR-FDA-NCI Cancer Biomarkers Collaborative
CCR Translations
CCR New Strategies
Molecular Pathways
Human Cancer Biology
BRCA1 Loss Preexisting in Small Subpopulations of Prostate Cancer Is Associated with Advanced Disease and Metastatic Spread to Lymph Nodes and Peripheral Blood
Natalia Bednarz; Elke Eltze; Axel Semjonow; Michael Rink; Antje Andreas; Lennart Mulder; Juliane Hannemann; Margit Fisch; Klaus Pantel; Heinz-Ulrich G. Weier; Krzysztof P. Bielawski; Burkhard Brandt
Cancer Therapy: Preclinical
The Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors Vatalanib and Pazopanib Potently Induce Apoptosis in Chronic Lymphocytic Leukemia Cells In vitro and In vivo
Julian Paesler; Iris Gehrke; Rajesh Kumar Gandhirajan; Alexandra Filipovich; Magdalena Hertweck; Felix Erdfelder; Sabrina Uhrmacher; Simon Jonas Poll-Wolbeck; Michael Hallek; Karl-Anton Kreuzer
Role of Type 1 IFNs in Antiglioma Immunosurveillance—Using Mouse Studies to Guide Examination of Novel Prognostic Markers in Humans
Mitsugu Fujita; Michael E. Scheurer; Stacy A. Decker; Heather A. McDonald; Gary Kohanbash; Edward R. Kastenhuber; Hisashi Kato; Melissa L. Bondy; John R. Ohlfest; Hideho Okada
Rapid and Robust Transgenic High-Grade Glioma Mouse Models for Therapy Intervention Studies
Nienke A. de Vries; Sophia W. Bruggeman; Danielle Hulsman; Hilda I. de Vries; John Zevenhoven; Tessa Buckle; Bob C. Hamans; William P. Leenders; Jos H. Beijnen; Maarten van Lohuizen; Anton J.M. Berns; Olaf van Tellingen
Imaging, Diagnosis, Prognosis
Prognostic Significance of TRAIL Signaling Molecules in Stage II and III Colorectal Cancer
Donal P. McLornan; Helen L. Barrett; Robert Cummins; Ultan McDermott; Cliona McDowell; Susie J. Conlon; Victoria M. Coyle; Sandra Van Schaeybroeck; Richard Wilson; Elaine W. Kay; Daniel B. Longley; Patrick G. Johnston
Molecular Analysis of Plasma DNA for the Early Detection of Lung Cancer by Quantitative Methylation-Specific PCR
Kimberly Laskie Ostrow; Mohammad O. Hoque; Myriam Loyo; Marianna Brait; Alissa Greenberg; Jill M. Siegfried; Jennifer R. Grandis; Autumn Gaither Davis; William L. Bigbee; William Rom; David Sidransky
Cancer Therapy: Clinical
Tremelimumab in Combination with Exemestane in Patients with Advanced Breast Cancer and Treatment-Associated Modulation of Inducible Costimulator Expression on Patient T Cells
Robert H. Vonderheide; Patricia M. LoRusso; Magi Khalil; Elaina M. Gartner; Divis Khaira; Denis Soulieres; Prudence Dorazio; Jennifer A. Trosko; Jens Rüter; Gabriella L. Mariani; Tiziana Usari; Susan M. Domchek
Results from a Phase I Clinical Study of the Novel Ii-Key/HER-2/neu(776–790) Hybrid Peptide Vaccine in Patients with Prostate Cancer
Sonia A. Perez; Nikoletta L. Kallinteris; Stratos Bisias; Panagiotis K. Tzonis; Katerina Georgakopoulou; Marighoula Varla-Leftherioti; Michael Papamichail; Anastasios Thanos; Eric von Hofe; Constantin N. Baxevanis
A Phase I Study of Foretinib, a Multi-Targeted Inhibitor of c-Met and Vascular Endothelial Growth Factor Receptor 2
Joseph Paul Eder; Geoffrey I. Shapiro; Leonard J. Appleman; Andrew X. Zhu; Dale Miles; Harold Keer; Belinda Cancilla; Felix Chu; Suzanne Hitchcock-Bryan; Laurie Sherman; Stewart McCallum; Elisabeth I. Heath; Scott A. Boerner; Patricia M. LoRusso
Letters to the Editor
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.
RSS Feeds